This site is intended only for healthcare professionals resident in Egypt

Search

Menu

Close

Sign InLog Out Our medicinesTherapy areasExplore contentExplore contentEventsDownloadable materialsVideosLet’s connectLet's ConnectContact usAsk a questionPfizer medical information

Menu

Close

Suspect & Detect About ATTR-CM Study Design Efficacy & Safety Profile Dosing MOD/MOA Important Safety Information Abbreviated Prescribing Information
Important Safety Information

Indications

VYNDAMAX™ is indicated for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization.1
 

Dosage and administration

The recommended dosage of VYNDAMAX™ 61 mg (one 61-mg tafamidis capsule) orally once daily. The capsules should be swallowed whole and not crushed or cut. If a dose is missed, instruct patients to take the dose as soon as remembered or to skip the missed dose and take the next dose at the regularly scheduled time. Do not double the dose. No clinically significant differences in the pharmacokinetics of tafamidis were observed following administration of a high fat, high calorie meal.1
 

Contraindications: None.1
 

Adverse Reactions:

In studies in patients with ATTR-CM, the frequency of adverse events in patients treated with tafamidis was similar to placebo.1
 

Specific Populations 

Pregnancy: VYNDAMAX™ may cause fetal harm when administered to a pregnant woman. Advise pregnant women of the potential risk to a fetus. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defects, loss, or other adverse outcomes.1

 

Lactation: There are no available data on the presence of tafamidis in human milk, the effect on the breastfed infant, or the effect on milk production. Tafamidis is present in rat milk. When a drug is present in animal milk, it is likely the drug will be present in human milk. Based on findings from animal studies which suggest the potential for serious adverse reactions in the breastfed infant, advise patients that breastfeeding is not recommended during treatment with VYNDAMAX™.1

MOA: mechanism of action; MOD: mechanism of disease.
 

MOA: mechanism of action; MOD: mechanism of disease.

References:VYNDAMAX™ (Tafamidis) Egyptian Drug Authority leaflet approval date 26/7/2021. Revision date: June 2021.

MOH Approval No. : HF0098OA171/082022

Invalidation Date : 11/08/2024

PP-VDM-EGY-0011

Support & Services

Adverse events should be reported. Adverse events can be reported to [email protected]

PfizerPro AccountPfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign inRegisterAccountSign Out

The product information provided in this site is intended only for Healthcare Professionals of Egypt. The products discussed herein may have different product labeling in different countries. 


Copyright © 2023 Pfizer biopharmaceutical LLC. All rights reserved.


PP-UNP-EGY-0241
You are leaving the Pfizer for Professionals website
​You are being directed to a third-party website.

Please note that this third-party website is not controlled by Pfizer for Professionals or subject to our privacy policy.

Thank you for visiting our site. We hope your visit was informative and enjoyable.
 
PP-UNP-EGY-0241
For Healthcare Professionals only

These pages are not intended for patients or members of the general public. This portal contains healthcare promotional content.
 

If you select ‘No’, you will be redirected to Pfizer.com, the global Pfizer website.
 

I confirm that I am a healthcare professional resident in Egypt.
 

PP-UNP-EGY-0241

Yes No
You are leaving the Pfizer for Professionals website You are being directed to a third-party website.

Please note that this third-party website is not controlled by Pfizer for Professionals or subject to our privacy policy.

Thank you for visiting our site. We hope your visit was informative and enjoyable.

PP-UNP-EGY-0241